General information about prostate cancer
Prostate cancer is the most frequently diagnosed type of cancer in men. The disease is considered part of the “natural history” of the prostate gland and only a small percentage of the tumors are aggressive and pose higher risk and, for these patients, immediate treatment is strongly advised. However, most prostate tumors are not aggressive and may be controlled effectively with conservative treatment.
Most patients diagnosed with early-stage prostate cancer and found to be at a low clinical risk (97%) live their lives and pass away for reasons other than prostate cancer.
It is important to be informed of the various methods used to diagnose prostate cancer, the tests to ascertain the aggressiveness of the tumor and the tools for customizing the treatment at all stages of the disease.
Oncotest-Teva offers a set of tests to guide treatment according to the biological characteristics at all stages of the disease:
Most newly diagnosed cases pose low risk (the tumor grows at a slow pace). The probability that the tumor will metastasize or become life-threatening is low. When at issue is early-stage prostate cancer, tests are used to obtain information for the purposes of ascertaining the degree of risk and for guiding and customizing treatment.
When at issue is a more advanced stage of prostate cancer, it is important for treatment to be guided by tests to customize biological therapy and to monitor the efficacy of that therapy.
In instances of a suspicion that the cancer developed due to a genetic mutation inherited from the parents, then, in order to ascertain whether the cancer developed due to genetic causes, it is important to conduct genetic tests and identify the genetic mutation.